From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Odalasvir structure.svg
Legal status
Legal status
CAS Number
PubChem CID
Chemical and physical data
Formula C60H72N8O6
Molar mass 1001.26368 g/mol
3D model (JSmol)

Odalasvir (INN,[1] previously known as ACH-3102)[2][3] is an investigational new drug in development for the treatment of hepatitis C.[4] It is an NS5A inhibitor.[5] The NS5A protein serves multiple functions at various stages of the viral life cycle, including viral replication. NS5A also plays a role in the development of interferon-resistance, a common cause of treatment failure.[6][7][8] It is under development by Achillion Pharmaceuticals.

See also[edit]


  1. ^ "International Nonproprietary Names for Pharmaceutical Substances (INN). RECOMMENDED International Nonproprietary Names: List 73" (PDF). who.int. World Health Organization. p. 38. Retrieved 5 December 2015. 
  2. ^ "Achillion Has Discovered and Developed a Comprehensive Portfolio of Antivirals for the Treatment of Hepatitis C". Achillion Pharmaceuticals. Retrieved 15 November 2015. 
  3. ^ Odalasvir at ChemIDplus
  4. ^ Walker, Tracey (December 2015). "Watch list 2016: top therapeutic areas: experts say you should follow these 6 therapeutic areas". Managed Healthcare Executive: 47. Retrieved March 12, 2016. 
  5. ^ Nakamoto S, Kanda T, Wu S, Shirasawa H, Yokosuka O. Hepatitis C virus NS5A inhibitors and drug resistance mutations. World J Gastroenterol. 2014 Mar 21;20(11):2902-12. doi: 10.3748/wjg.v20.i11.2902. PMID 24659881
  6. ^ ACH-3102 resources. Achillion pharmaceuticals. Winter 2011. Accessed May 2012.
  7. ^ Achillion gets FDA incentives for hepatitis C drug. Associated Press. 15 May 2012.
  8. ^ Levin, Jules. Preclinical characteristics of ACH-3102. Conference report. European Association for the Study of the Liver, 47th Annual Meeting. April 18th - 22nd 2012. Barcelona, Spain